Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05388929 · ClinicalTrials.gov registry record · Phase 4
Methocarbamol in Ventral and Inguinal HR
A Phase 4 study of Ventral Hernia and Inguinal Hernia, sponsored by Prisma Health-Upstate.
- Active
- Registry status
- Phase 4
- Development phase
- 164
- Enrollment target
- 1
- Study location
NCT05388929 is a Phase 4 study of Ventral Hernia and Inguinal Hernia that is active but no longer recruiting, run by Prisma Health-Upstate. The registered enrollment target is 164 participants, above the 134-participant average among 18 other Ventral Hernia trials with a reported enrollment target (22% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05388929, a Phase 4 study of Ventral Hernia and Inguinal Hernia, is active but no longer recruiting, sponsored by Prisma Health-Upstate.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 164 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to gather information on methocarbamol as a pain management treatment for ventral or inguinal hernia repair. Methocarbamol has been part of the pain management treatment for both inpatient and outpatient procedures at Prisma Health. This study will compare the outcomes of patients who receive methocarbamol, those who receive the standard opioid pain management treatment, and those who receive methocarbamol plus the standard opioid pain management treatment. Participants will be randomized into one of the study groups listed below. Primary ventral hernia repair or inguinal hernia repair: Group 1: standard opioid after surgery Group 2: methocarbamol after surgery Open or robotic ventral hernia repair outpatient: Group 1: standard opioid after surgery Group 2: standard opioid plus methocarbamol after surgery Open or robotic ventral hernia repair inpatient: Group 1: standard opioid at discharge Group 2: standard opioid plus methocarbamol at discharge A total of 200 participants will be included in the study. Participation will last for about 30 days after surgery.
Conditions Studied
Interventions
- DRUG Methocarbamol
- DRUG Standard Opioid
- DRUG Standard opioid plus methocarbamol
Study Locations (1)
South Carolina
- Prisma Health - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2022-06-23 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05388929
The ClinicalTrials.gov registry entry for NCT05388929 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 134-participant average among 18 other Ventral Hernia trials with a reported enrollment target (22% higher). The listed sponsor is Prisma Health-Upstate, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ventral Hernia appearing as the primary indexed condition, and to 3 interventions - of which Methocarbamol is the first listed.
NCT05388929 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT05388929 about?
NCT05388929 is a clinical study titled "Methocarbamol in Ventral and Inguinal HR". The purpose of this study is to gather information on methocarbamol as a pain management treatment for ventral or inguinal hernia repair. Methocarbamol has been part of the pain management treatment for both inpatient and outpatient procedures at Prisma Health. This study will compare the outcomes ...
What is the current status of trial NCT05388929?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 164 participants. The study started on 2022-06-23. Estimated completion is 2026-12.
What conditions does trial NCT05388929 study?
This clinical trial studies the following conditions: Ventral Hernia, Inguinal Hernia.
What interventions are being tested in trial NCT05388929?
The interventions under investigation include: Methocarbamol (DRUG), Standard Opioid (DRUG), Standard opioid plus methocarbamol (DRUG).
Who is sponsoring clinical trial NCT05388929?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05388929 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ventral Hernia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AFFIX: Post-market Study of MaxTack™ Motorized Fixation Device in Subjects Undergoing Ventral Hernia Repair
RECRUITING · NA
-
Robotic Versus Open Ventral Hernia Repair
RECRUITING · NA
-
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair
RECRUITING · Phase 2
-
Clinical Investigation of the da Vinci Surgical System
ACTIVE NOT RECRUITING · NA
-
Post-operative Pain Control-TAP Block Using Exparel vs. Marcaine for Hernia Repairs
ACTIVE NOT RECRUITING · Early Phase 1
-
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Hernia Surgery (Enable Hernia Repair)
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.